In addition to forming a diverse consortium of participants that includes patients, families, academic researchers, clinicians and the pharmaceutical industry, Total Cancer Care has also formed a partnership with M2Gen.
M2Gen is a wholly owned subsidiary of Moffitt Cancer Center and was formed to manage the Total Cancer Care consortium and a collaboration with Merck & Co. to develop personalized cancer treatments for patients using molecular technology. M2Gen is responsible for the tissue collection from patients enrolled on the Total Cancer Care protocol and the related Total Cancer Care database. M2Gen analyzes these tissue samples to identify the biological markers unique to each tumor. Analyzing patients’ responses to specific treatments will lead to more individualized care aimed at providing rapid improvement with fewer side effects.
For more information about M2Gen, visit http://www.m2gen.com/ or call 813.384.5023.